| Detected | Trial | Change |
|---|---|---|
| 2026-05-27 | NCT06516887 Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
Trial terminated — check why_stopped for reason |
| 2026-05-27 | NCT06516887 Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
critical why stopped: null → "Investigational drug limitations" |
| 2026-05-27 | NCT06516887 Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
Enrollment reduced: 44 -> 4 participants |
| 2026-05-27 | NCT06516887 Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
date change Primary completion moved earlier: 2027-09-01 -> 2026-05-21 |
| 2026-05-27 | NCT06516887 Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma |
date change Completion moved earlier: 2027-09-01 -> 2026-05-21 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia… | Primary Myelofibrosis | Active, Not Recruiting |
| Phase 2 | |||
| NCT04858256 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | T-Cell Neoplasm | Recruiting |
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and… | Myelofibrosis | Recruiting |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic… | Accelerated Phase Myeloproliferative Neoplasm | Recruiting |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Leukemia, Myelomonocytic, Chronic | Recruiting |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of… | Acute Myeloid Leukemia | Recruiting |
| NCT06782373 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS… | VEXAS | Recruiting |
| NCT07394153 | Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have… | Myelofibrosis，MF | Recruiting |
| NCT06052618 | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric… | KSHV Inflammatory Cytokine Syndrome (KICS) | Recruiting |
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Myelofibrosis | Not Yet Recruiting |
| NCT07226713 | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That… | Prostate Cancer | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT05531786 | Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic… | Graft vs Host Disease | Recruiting |
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric… | Myelodysplastic Syndromes | Recruiting |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome | Myelodysplastic Syndromes | Not Yet Recruiting |
| Phase 1 | |||
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With… | Recurrent Mantle Cell Lymphoma | Recruiting |
| Early Phase 1 | |||
| NCT06414681 | Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher… | Myelofibrosis，MF | Recruiting |